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Background: To evaluate the role of RapidArc (RA) for stereotactic radiosurgery (SRS) of benign brain lesions in
comparison to GammaKnife (GK) based technique.
Methods: Twelve patients with vestibular schwannoma (VS, n = 6) or cavernous sinus meningioma (CSM, n = 6)
were planned for both SRS using volumetric modulated arc therapy (VMAT) by RA. 104 MV flattening filter free
photon beams with a maximum dose rate of 2400 MU/min were selected. Data were compared against plans
optimised for GK. A single dose of 12.5 Gy was prescribed. The primary objective was to assess treatment plan
quality. Secondary aim was to appraise treatment efficiency.
Results: For VS, comparing best GK vs. RA plans, homogeneity was 51.7 ± 3.5 vs. 6.4 ± 1.5%; Paddick conformity
Index (PCI) resulted 0.81 ± 0.03 vs. 0.84 ± 0.04. Gradient index (PGI) was 2.7 ± 0.2 vs. 3.8 ± 0.6. Mean target dose was
17.1 ± 0.9 vs. 12.9 ± 0.1 Gy. For the brain stem, D1cm3 was 5.1 ± 2.0 Gy vs 4.8 ± 1.6 Gy. For the ipsilateral cochlea,
D0.1cm3 was 1.7 ± 1.0 Gy vs. 1.8 ± 0.5 Gy. For CSM, homogeneity was 52.3 ± 2.4 vs. 12.4 ± 0.6; PCI: 0.86 ± 0.05 vs. 0.88 ±
0.05; PGI: 2.6 ± 0.1 vs. 3.8 ± 0.5; D1cm3 to brain stem was 5.4 ± 2.8 Gy vs. 5.2 ± 2.8 Gy; D0.1cm3 to ipsi-lateral optic
nerve was 4.2 ± 2.1 vs. 2.1 ± 1.5 Gy; D0.1cm3 to optic chiasm was 5.9 ± 3.1 vs. 4.5 ± 2.1 Gy. Treatment time was 53.7 ±
5.8 (64.9 ± 24.3) minutes for GK and 4.8 ± 1.3 (5.0 ± 0.7) minutes for RA for schwannomas (meningiomas).
Conclusions: SRS with RA and FFF beams revealed to be adequate and comparable to GK in terms of target
coverage, homogeneity, organs at risk sparing with some gain in terms of treatment efficiency.
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Vestibular Schwannoma (VS) is a benign tumor that
originates from the vestibular portion of the eighth cranial
nerve. The incidence is 1 in 100,000. The patients due to
the mass effect may note symptoms like disequilibrium,
vertigo, tinnitus and headache. However, most patients
complain from progressive unilateral hearing decline.
Earlier detection with widespread use of MR imaging
prompts the patient and the clinician to treatment, when* Correspondence: lucozzi@iosi.ch
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unless otherwise stated.the patient still has useful hearing. Management options
are observation, microsurgery, stereotactic radiosurgery
(SRS) or fractionated stereotactic radiotherapy.
Intracranial meningiomas are mostly benign tumors
(WHO grade I) in 90-95% of the cases. Clinical behavior
and treatment strategies depend on the location, size
and proximity to critical structures. Surgical treatment is
preferred for easily accessible tumors and gross total re-
section achieves >90% local control rates. However, sur-
gery for the meningiomas in the skull base like cavernous
sinus meningiomas (CSM) carries high morbidity risk.
SRS for CSM with maximum diameter less than 3 to 4 cmral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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high local control rates with reasonable morbidity [1].
The stereotactic radiosurgery (SRS) approach to the
treatment of small to medium sized VS or meningioma
is well consolidated in literature with results demonstrat-
ing both very high local control rates (larger than 90%
up to 96-98%) as well as minimal toxicity (5 yr radiation
related toxicity as low as ~5-10%) [2-7]. Recent data sug-
gest that good control rates and low side effects can be
achieved with doses around 12-13 Gy [7].
For VS, the rate of post-treatment hearing preservation
is reported to be strongly correlated with the radiation
dose to the cochlea. Mean cochlea doses below 3.7 and
4.8 Gy are reported to be safe for retaining useful hearing
[8]. QUANTEC guideline recommends maximum dose to
be limited to 12-14 Gy for hearing preservation [9]. For
the CSM, the highest risk of toxicity in SRS, might derive
from radiation induced optic neuropathy. QUANTEC [10]
identified that with near-to-maximum doses <8 Gy, the
risk should be rare.
Several different techniques have been applied in the last
decades; these were based either on the usage of dedicated
delivery systems or on general purpose linear accelerators,
modified or adapted to SRS.
Dedicated systems included mainly the GammaKnife
(GK) originally developed by Leksell [11] and more re-
cently the CyberKnife, derived from the intuition of
Adler [12].
Sun [13] demonstrated on a group of 200 patients that
a 5 year control rate of 93% was expected with a 92%
hearing preservation for VS patients treated with <14 Gy
and GK. Similar results were reported by Hasegawa [7]
on a cohort of 400 patients followed for more than
10 years. Zeiler [14] showed efficacy of GK based radio-
surgery of CSM on a cohort of 30 patients. Balagamwale
[15] showed, on 145 patients with meningiomas, the role
of various dose-related indices suggesting the need of
high conformality of treatments. Starke [16] analysed
retrospectively 225 patients with skull base meningioma,
of these 146 received GK treatment after surgery. This
study showed actuarial progression free survival rate of
96% at 5 years (79% at 10 years).
Based on general purpose linear accelerators, common
techniques included the usage of multiple conformal
arcs (with cones or micro-MLC) or multiple static inten-
sity modulated (IMRT) fields. Today, IMRT evolved into
volumetric modulated arc therapy (VMAT) pioneered in
its RapidArc (RA) mode by Otto [17]. The role of RA
was assessed for SRS for benign lesions in a number of
studies. Fogliata [18] demonstrated the possibility to
achieve target coverage equivalent to Helical Tomother-
apy in the presence of improved sparing of organs at
risk. Lagerwaard [19] approached the usage of RA for
VS demonstrating increased conformality and advanceddose shaping potential compared to conformal arcs. Sub-
ramanian [20] investigated the role of RA on (large)
AVMs and reported well-tolerated treatments with min-
imal toxicity. More in general, Mayo [21], Clark [22] and
Wolff [23] analysed the general role of RA for SRS and
demonstrated relevant improvements in plan quality and
also in delivery efficiency when compared to alternative
techniques (e.g. vs. CyberKnife in the study of Mayo). A
relevant aspect of RA based SRS is the possibility to ac-
curately plan with the existing tools. Audet [24] demon-
strated the absence of lower limits in the size of lesions
for which RA plans can be optimized. Fogliata [25] dem-
onstrated that treatment planning and dose calculation
tools can be properly tailored for SRS planning and cal-
culated dose can be nicely matched to delivery.
The purpose of the present study is to assess the po-
tential differences and relative merits of the RA based
radiosurgery in comparison to the GK approach. The
primary aim is to quantify dose-related objective differ-
ences of clinical relevance. The secondary aim of the
study is to determine the delivery efficiency of the two
methods in terms of treatment time (not including posi-
tioning and imaging procedures which are very different
and not comparable between the systems).
Materials and methods
Patients, volumes and dose prescriptions
Six VS cases who were treated with RA technique and 6
CSM cases who were treated by GK formed the basis of
this study. They were randomly selected from the pool of
previously treated patients. Median age was 40 years
(range, 15–63) for VS and 64 years (range, 57–66) for
CSM. Male/female ratio was 5/1 for VS and 2/4 for CSM.
VS and CSM cases had mean tumor volumes of 4.2 cc
(range, 1.2-8.5 cc) and 7.9 cc (range, 3.3-13.7 cc), respect-
ively. They represented the range of target sizes and
shapes mostly observed in SRS practice.
CT scans with contrast were acquired with 1.3 mm
slice thickness covering the entire head of the patients.
MR image acquisition was performed with head coil on
a 1.5 or 3 Tesla MR. T1 sequences with gadolinium was
used for Gross Target Volume (GTV) delineation and
CISS sequence was used for internal auditory structures.
All images were co-registered for target volume and organ
at risk (OAR) delineation. GTV definition was performed
by experienced radiation oncologists and neurosurgeons
based on appropriate multimodality imaging (CT and MR).
No margins were added to the GTV to define the Planning
Target Volume (PTV). There is no absolute consensus
about the need to add a little margin to GTV when non in-
vasive immobilisation is used [26] but in this study, to per-
form an unbiased comparison, this was not adopted. OARs
were accordingly defined by the same team. Data transfer
between different systems was performed by means of
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and RA planning.
The study was performed in agreement with the Helsinki
declaration and with internal institutional ethical review
board approval.
For the VS patients, the brain stem and the ipsi-lateral
cochlea were defined as the organs at risk. For the CSM
patients, the OAR were the brain stem, the ipsi-lateral
optic nerve and the chiasm.
Dose prescription and planning objectives
A single fraction dose of 12.5 Gy was prescribed to all
cases. All plans were normalised to guarantee the same
minimum coverage to GTV so that V98 = 98% of the pre-
scribed dose. A common normalisation is mandatory for
any comparative purpose. Planning objectives were kept
as simple as possible and identical between the different
systems: minimisation of mean and near-to-maximum
doses to the organs at risk without compromising target
coverage. Observed differences between dose distribu-
tions would therefore reflect the inherent features of
those and allow a more informed choice between differ-
ent solutions. To further explore technical capabilities
of linac based SRS, RA plans were optimised with two
strategies: TB_1: enforcing minimisation of the homogen-
eity, that means minimisation of the near-to-maximum
dose D2%. The second strategy, TB_2, aimed to mimic the
GK planning philosophy with no upper constraints to the
GTV dose. TB_1 plans have been considered to inves-
tigate if RA and FFF could guarantee adequate target
coverage and OARs sparing while eliminating the tar-
get over-irradiation which could constitute a change of
paradigm in the SRS planning practice. Similarly to the
above, GK_1 plans were obtained by applying strong
priority to the maximisation of the dose gradient out of
the target while GK_2 aimed also to exploit maximal
OAR sparing.
SRS with RapidArc
For all patients in the study, RA plans were optimised
using 4–8 partial non-coplanar arcs. Collimator and
couch pedestal angles as well as single arc lengths were
optimised for each individual case with trial and error
procedure. Inverse planning was performed with the
Varian Eclipse treatment planning system (version 10)
and dose calculation with the Acuros-XB algorithm with
a grid resolution of 1 mm. All plans were designed for a
10 MV flattening filter free beam generated by a TrueBeam
(TB) linac equipped with a high definition MLC (120 leaves
with a spatial resolution at isocenter of 2.5 mm in the
region of interest for the study). To improve healthy tis-
sue sparing, the jaw tracking option of TB was enabled
for all patients. Similar dosimetric results could be achiev-
able with the lower 6 MV FFF beam but the choice of10 MV was made to benefit from the higher nominal dose
rate (2400 MU/min versus 1400 MU/min).
SRS with GammaKnife
GK plans were optimised for all patients using the Elekta
GammaPlan treatment planning system (version 10.1)
for a GK Perfexion treatment unit. The GK has 192 Co-
60 sources, which are placed on 8 sectors. Each sector
can move in a linear direction back and forth over the
internal collimation system with several stopping posi-
tions. Each position corresponds to a different size colli-
mator. Each sector has 24 sources, 3 different size of
open collimators are available for each source (16 mm,
8 mm, 4 mm) as well as a blocked collimator. Therefore
there is no more requirements to manually change collima-
tion helmets as with earlier versions of GK. All sources are
used by default. However to protect the organs at risk in
the neighborhood of the target, the optimization process
allows to block one or more sectors or even individual
sources. Because each of the 8 sectors can move inde-
pendently, it is possible to create plans with composite
multiple isocentres (shots) where each sector is of differ-
ent collimator size. This can be done with manual trial
and error procedure or with inverse planning (as in the
present study): the algorithm can automatically block the
sectors/sources, which come through the OAR. Concerning
GK_1 plans, for the VS cases, an average of 26 ± 8 shots
were used (range 14–36) with 8 mm collimator in 35% and
4 mm in 57% of the cases (only 1 shot for a single patient
was associated to a collimator of 16 mm). For CSM cases,
25 ± 7 shots were used (range:18–32) with 4 mm in 51% of
cases, 8 mm in 45% and 16 mm in 4% of the total shots.
Concerning GK_2 plans, for the VS cases and average of
14 ± 4 shots (range 10–21) were used with a proportion of
collimator sizes similar to GK_1. For the CSM cases the
number of shots was 20 ± 6 (range: 15–32),
Dose calculation was performed with the TMR classic
algorithm. Calculation matrix was set to 2.5 mm for all
plans. All dose data were exported in DICOM format and
imported in Eclipse for quantitative analysis (eliminating
therefore one important bias risk from the usage of diffe-
rent methods for DVH calculation).
Analysis tools
For each patient, dosimetric parameters were scored and
plan quality was measured from dose volume histogram
(DVH) analysis. For GTV, target coverage (minimum as
D98%, maximum as D2%) was reported. Homogeneity was
scored as (V5%-V95%)/Dmean as well as in terms of standard
deviation. Paddick Conformity and Gradient indexes (PCI
and PGI) were defined and reported [27,28]. PCI = TVPIV
2 /
(TV x PIV) where TV is the target volume, TVPIV is the
target volume irradiated at prescription dose and PIV is
the prescribed isodose volume; PGI = V50%PIV/PIV where
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dose. In addition, a Dose Gradient Measure (DGM) was
defined as the difference of the radii of the equivalent
spheres of the 100% and 50% isodose volumes. For OARs,
the mean dose, the maximum dose (Dxcm3) and appropri-
ate values of VxGy (volume receiving at least x Gy) were
scored depending on the individual organ. Guidelines of
International Commission on Radiation Units and Mea-
surements (ICRU) 83 report were applied as much as pos-
sible [29]. No analysis on the “body” healthy tissue was
performed since the dose matrices of the GK did not cov-
ered the entire volume involved.
Treatment time for RA plans was measured at the
linac while for GK plans was computed by the planning
system. The assessment also did not accounted for door-
to-door time estimate since this might depend upon sev-
eral variables (local procedures, resources, institutional
policies) that might be irreproducible between different
centers. We preferred to limit the analysis to objective
quantities, independent from the local boundary condi-
tions. This assessment did not included pre-treatment
quality assurance verification since this is part of the
planning acceptance procedure and depends significantly
on the methodology used. Both systems (GK and TB
with RA) are in clinical use (also for SRS) since long
time and several publications addressed the plan deliver-
ability issue in detail.
Results
Figure 1 shows the isodose distribution for the four plans
in axial, coronal and sagittal planes for a representative VS
case. Figure 2 shows the same for a CSM case. Color-wash
threshold was set between 5 and 18 Gy. From the figures,GK_1 GK_2
Figure 1 The isodose distribution for the four plans in axial, coronal a
Colorwash threshold is set between 5 and 18Gy.it is possible to derive the qualitative features of the plans:
equivalent coverage between all techniques (required at
planning); intentionally homogeneous dose distributions
for TB_1 plans and systematic over-irradiation of target,
as from conventional practice with SRS, for GK_1, GK_2
and TB_2.
Figure 3 shows the average DVH for target volume and
organs at risk for the VS cases and the four techniques
while Figure 4 shows the same for the CSM group.
Table 1 summarises the quantitative analysis of the
DVH for the VS cases for GTV and organs at risk.
Table 2 presents the same for the CSM cases.
From a qualitative point of view, there are some general
features of GK and RA plans. In the absence of upper
constraints, GK generates a much more intense over-
irradiation of the target, also compared to TB_2. On the
contrary, RA plans (both TB_1 and TB_2) can shape
more the dose around challenging OARs compared to
the simpler GK_1 planning approach. GK_2 plans allowed
further sparing of OARs without compromising other
parameters.
The chosen normalisation to V98 = 98% to guarantee
the same coverage for all techniques, reflected into some
little variability in the minimum dose level encompass-
ing the entire target. This resulted 70% for all VS plans
and between 80 and 85% for all CSM plans. Conformal-
ity (PCI) resulted equivalent between all the groups of
plans while significant difference were observed in other
parameters. More homogeneous dose distributions to
the target were achieved with RA (intentionally for TB_1
but also for TB_2, depending on the clinical case) if
needed or desired. In the case of VS the gain in homogen-
eity was ~17% for TB_2 and ~45% for TB_1 compared toTB_1 TB_2
nd sagittal planes for a representative Schwannoma case.
GK_1 TB_1 TB_2
 GK_1 
Figure 2 The isodose distribution for the four plans in axial, coronal and sagittal planes for a representative Meningioma case.
Colorwash threshold is set between 5 and 18 Gy.
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40% for TB_1. This effect derived from the corresponding
reduction of the near-to-maximum dose to GTV (~4 Gy
(18%) sparing for TB_2 and ~9 Gy (41%) for TB_1 for VS
and ~8.5 Gy and 7 Gy for CSM). The trade-off was an in-
crease of gradients (DGM) that was observed for RAFigure 3 Average DVH for target volume and organs at risk for the scalthough this was limited to 1 mm in the case of GK vs.
TB_2 (similarly reflected in the PGI). This trade-off in the
gradients was associated to a (frequently) statistically sig-
nificant improved sparing of the organs at risk. In the case
of VS, the results obtained for the ipsi-lateral cochlea
revealed that, depending on the optimisation strategyhwannoma patients and the four techniques.
Figure 4 Average DVH for target volume and organs at risk for the meningioma patients and the four techniques.
Table 1 Summary of dose volume histogram analysis for GTV, brain stem and ipsilateral cochlea for VS patients
GK_1 GK_2 TB_1 TB_2 p
PTV vol [cm3]: 4.22 ± 2.85 Range: [1.20; 8.50]
Mean [Gy] 17.1 ± 0.9 17.1 ± 0.8 12.9 ± 0.1 16.0 ± 0.6 a, b, c, d
D2% [Gy] 22.7 ± 1.2 23.0 ± 0.8 13.4 ± 0.2 18.8 ± 1.1 a, b, c, d
D98% [Gy] 12.25 ± 0.0 12.25 ± 0.0 12.25 ± 0.0 12.25 ± 0.0 n.s.
St. dev [Gy] 2.7 ± 0.3 2.8 ± 0.2 0.3 ± 0.1 1.7 ± 0.3 a, b, c, d
Homogeneity [%] 51.7 ± 3.5 51.8 ± 1.2 6.4 ± 1.5 35.0 ± 4.9 a, b, c, d
PCI 0.81 ± 0.03 0.78 ± 0.04 0.83 ± 0.07 0.84 ± 0.04 c, d
PGI 2.7 ± 0.2 2.8 ± 0.2 5.1 ± 0.7 3.8 ± 0.6 a, b, c, d
DGM [cm] 0.4 ± 0.1 0.4 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 a, b, c, d
Brain stem vol [cm3] = 21.50 ± 8.37 Range: [8.69; 32.70]
D1cm3 [Gy] 5.1 ± 2.0 5.4 ± 2.2 5.7 ± 2.1 4.8 ± 1.6 n.s.
V8Gy [%] 1.9 ± 1.7 2.3 ± 1.8 2.5 ± 1.9 1.1 ± 1.0 a, b, d
V10Gy [%] 0.6 ± 0.5 0.8 ± 0.6 0.8 ± 0.7 0.2 ± 0.2 a, b, d
V12Gy [%] 0.1 ± 0.1 0.2 ± 0.2 0.03 ± 0.04 0.01 ± 0.01 a
Ipsilateral cochlea vol [cm3] = 0.10 ± 0.01 Range: [0.02;0.13]
Mean [Gy] 6.6 ± 2.9 3.3 ± 0.8 5.5 ± 2.2 4.1 ± 0.9 a, b, c
D0.1cm3 [Gy] 4.0 ± 1.8 1.7 ± 1.0 3.1 ± 1.2 1.8 ± 0.5 a, b, c
D30% [Gy] 7.3 ± 3.2 3.6 ± 0.8 6.2 ± 2.4 4.7 ± 1.1 a, b, c, d
Statistical significance p: a = GK_1 vs TB_1, b = GKv vs TB_2, c = GK_2 vs TB_1, d = GK_2 vs TV_2; n.s. = not significant. PCI = Paddick Conformity Index,
PGI = Paddick Gradient Index, DGM = Dose Gradient measure. Dx% = Dose at x% of the volume.
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Table 2 Summary of dose volume histogram analysis for GTV, brain stem, optic chiasm and ipsi-lateral optic nerve for
CSM patients
GK_1 GK_2 TB_1 TB_2 p
PTV vol [cm3]: 7.28 ± 4.2 Range: [3.3; 13.7]
Mean [Gy] 17.4 ± 0.9 17.4 ± 0.9 13.6 ± 0.2 14.2 ± 0.5 a, b, c, d
D2% [Gy] 22.9 ± 1.4 23.2 ± 1.3 14.4 ± 0.4 15.8 ± 0.8 a, b, c, d
D98% [Gy] 12.25 ± 0.0 12.25 ± 0.0 12.25 ± 0.0 12.25 ± 0.0 -
St. dev [Gy] 2.8 ± 0.2 2.8 ± 0.2 0.5 ± 0.1 0.9 ± 0.3 a, b, c, d
Homogeneity [%] 52.3 ± 2.4 52.7 ± 1.8 12.4 ± 0.6 21.1 ± 0.5 a, b, c, d
PCI 0.86 ± 0.05 0.81 ± 0.06 0.86 ± 0.06 0.88 ± 0.05 c, d
PGI 2.7 ± 0.1 2.6 ± 0.1 3.9 ± 0.7 3.8 ± 0.5 a, b, c, d
DGM [cm] 0.5 ± 0.1 0.5 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 a, b, c, d
Brain stem vol [cm3] = 19.9 ± 4.3 Range: [15.36; 26.1]
D1cm3 [Gy] 5.4 ± 2.8 5.5 ± 2.6 5.8 ± 2.0 5.2 ± 2.8 n.s.
V8Gy [%] 2.3 ± 2.7 2.3 ± 2.6 1.8 ± 1.7 1.8 ± 1.6 n.s.
V10Gy [%] 0.7 ± 0.8 0.7 ± 0.7 0.5 ± 0.6 0.4 ± 0.4 n.s.
V12Gy [%] 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.0 ± 0.1 n.s.
Optic chiasm vol [cm3] = 0.5 ± 0.3 Range: [0.3; 0.9]
D0.1cm3 [Gy] 6.8 ± 3.4 5.9 ± 3.1 5.1 ± 2.9 4.5 ± 2.1 a, b, d
Ipsilateral optic nerve vol [cm3] = 0.5 ± 0.1 Range: [0.4;0.5]
D0.1cm3 [Gy] 4.2 ± 2.1 4.2 ± 2.1 2.9 ± 1.6 2.1 ± 1.5 a, b, c, d
Statistical significance p: a = GK_1 vs TB_1, b = GK_1 vs TB_2, c = GK_2 vs TB_1, d = GK_2 vs TB_2; n.s. = not significant. PCI = Paddick Conformity Index,
PGI = Paddick Gradient Index, DGM = Dose Gradient measure. Dx% = Dose at x% of the volume.
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near-to-maximum doses to very low values. Interestingly,
GK plans showed the greatest improvement in sparing this
OAR (GK_1 vs GK_2) when explicit constraints were ap-
plied or not. Mean dose with GK_2 and TB_2 resulted to
be compatible with the range of tolerable levels for useful
hearing retention. In the case of meningiomas, the near-to-
maximum dose to optic chiasm was reduced of ~34%
(25%) for TB_2 (TB_1) vs GK_1 and of ~24% (~15%) vs
GK_2. The same parameter for the ipsi-lateral optic nerve
was reduced by a factor 2 with TB_2 (31% for TB_1) vs.
GK_1 or GK_2.
Treatment efficiency was scored by the treatment time
(defined excluding the time needed for patient positioning
and imaging procedures). This parameter ranged from 53
to 84 minutes for GK plans (with GK_2 plans requiring
6–20 minutes less than GK_1). Treatment time was con-
sistently ~5 minutes for all TB cases.
Discussion
Role of SRS in the treatment of intracranial benign tumors
has been well established over years. Various techniques
using frame-based or frameless positioning and localisa-
tion systems have proved their success. Both dedicated
and general purpose radiotherapy equipments with special
SRS related improvements have been developed. Compar-
isons of dosimetric quality and clinical results have always
been an ongoing subject of investigation.The usage of RA with flattening filter free beams was
investigated in this study for the delivery of SRS treat-
ments to VS and CSM. RA plans were compared versus
GK plans and dose-related analysis was performed. In
general, plans of high quality were obtained for all tech-
niques but some general features were outlined. A limit of
any planning study is the difficulty to factorise between re-
sults inherent to the techniques investigated or imputable
to the choices made by the actual planners using the tools.
The present study was done aiming to achieve the best
plans from both systems and, for the more investigational
group of RA, efforts were made to understand the degree
of flexibility of the technique for three important features:
dose gradients, target heterogeneity and OAR sparing. In
general, GK plans confirmed the inherent capability of the
technique to emphasize conformality and rapid isotropic
dose fall-off associated to a good OAR sparing if required
and at the price of a greater target heterogeneity. RA dem-
onstrated a significant flexibility in the trade-off between
target homogeneity and OAR sparing. The price paid was
an inferior isotropic falloff and a shallower gradient. Clin-
ical data would be now needed to demonstrate if the mod-
est differences in dose gradient and patterns of OAR
sparing could also lead to reduced side effects. The data
from the present study suggest, at least, that treatment
plan individualisation can be achieved with both RA and
GK. Target coverage was defined equal between tech-
niques by definition; for this reason, a further measure
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measures. RA and GK resulted in equivalent conformality
while plans from GK showed sharper dose gradients.
Although common practice in SRS emphasizes high
conformality and sharp dose fall-off over target dose
homogeneity, there is no absolute evidence or consen-
sus that improved target homogeneity would be detri-
mental for disease control. An interesting and not
intuitive correlation between homogeneity and gradient
indexes and treatment related toxicity was observed and
reported by Balagamwala [15]. In that study, patients
with PGI larger than 3.0 were associated with lower in-
cidence of motor or auditory deficits compared to pa-
tients treated with sharper dose distributions. Under
these assumptions, the TB_1 and TB_2 plans would fit
in the favourable category. The same study correlated
also homogeneity to toxicity (dizziness) finding that a
maximum dose <2 times the prescription (heterogeneity
index) dose would have been recommended. Data from
the present study suggest therefore that all techniques
(GK or RA) would meet the criterion. The flexibility of
RA in minimising the D2% and the homogeneity indices
(HI or standard deviation) could be considered as an
additional tool available whenever the clinical problem
would demand for it and, in any case, would not neces-
sarily be always beneficial but at the same time it should
not be negative.
A potential criticism to the data presentation of this
study could arise from the dose normalisation chosen for
the comparison. All plans were normalised so that V98 =
98% of the prescribed dose. This procedure, might look un-
usual in SRS practice but it is an obvious mandatory step
in any comparative investigation to give relative meaning
to any observed difference between the techniques studied.
Conversely, the normalisation choice did not introduce any
violation of the main SRS prescription paradigm that
conventionally requires that the dose should be pre-
scribed to the highest isodose encompassing the target
volume (D100%) and that this should fall in the range 50-
90%. In the present study, D100% ranged from 80 to 85% for
CSM and was 70% for the VS cases and for all techniques.
The secondary end point of the study was the assess-
ment of the treatment efficiency. In this case, the data
reported demonstrate that, compared to a treatment
time of ~1 hour for GK, the same delivery can be com-
pleted in less than 5 minutes with RA. Strength of the
GK sources can obviously compensate only partially this
time difference. On the contrary, the benefit of the
usage of flattening filter free beams with the very high
nominal dose rate of 2400 MU/minute is mitigated in
this study by the number of partial arcs selected for the
plans. The latter was in the range of 4–8 in order to guar-
antee the desired high quality of dose distributions but does
not necessarily correspond to an absolute best selection.Further geometrical optimisation of RA plans might lead to
reduced number of arcs and to further reduction of the ex-
pected delivery time. In the extreme case of a single full
arc, with the prescription of 12.5 Gy and for a beam of
10 MV FFF, the minimum beam on time would have been
1.9 minutes and this would constitute the lower limit for
this case of RA application. This analysis is also consistent
with the data by Prendergast [30] who reported an average
treatment time of ~1.2 minutes for a variety of dose frac-
tions ranging from 5 Gy to 16 Gy. With the data presented
here, it is obvious that SRS treatments can be easily fit into
routine time slots if RA is applied and that, as a conse-
quence, minimal perturbation of the standard clinical
workflow and high patient throughput can be granted also
in clinical environments with relevant incidence of SRS
treatments.Conclusion
The present study assessed in silico at planning level, the
differences and relative merits of the RA based radiosur-
gery in comparison to the GK approach. Both approaches
resulted in fully acceptable plans with different dosimetric
characteristics. A possibly increased homogeneity of target
dose with linac based SRS was associated to a modest de-
terioration of the dose gradient. Depending on the opti-
misation strategy, both GK and TB achieved high sparing
of OARs. The clinical relevance of these features should
be proven in a prospective setting. Similarly, the results
for treatment time demonstrated the major gain poten-
tially offered by RA SRS for the clinical throughput and
the workflow logistic in a department.
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